Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) is a genomic medicine company whose news flow centers on clinical data, regulatory interactions, collaborations and financial updates across its neurology‑focused pipeline. Company announcements emphasize investigational programs in Fabry disease, chronic neuropathic pain and prion disease, along with progress in its zinc finger epigenetic regulation and AAV capsid platforms.
A major theme in recent SGMO news is the development of isaralgagene civaparvovec (ST‑920), a wholly owned investigational gene therapy for adults with Fabry disease. Press releases detail topline and updated results from the registrational Phase 1/2 STAAR study, including positive mean annualized estimated glomerular filtration rate (eGFR) slopes at 52 and 104 weeks, stability of cardiac endpoints, biomarker trends and quality‑of‑life measures. Regulatory milestones, such as FDA agreement to use eGFR slope as an endpoint for an accelerated approval pathway and acceptance of a rolling Biologics License Application (BLA) submission, are also key subjects.
Investors following SGMO news can also track developments in the Phase 1/2 STAND study of ST‑503 for intractable pain due to small fiber neuropathy, including FDA Fast Track Designation, site activation and recruitment updates. Additional releases describe preclinical and regulatory progress for ST‑506 in prion disease, as well as business development activities like the capsid license agreement with Eli Lilly and Company and other collaboration‑related revenues.
Quarterly earnings releases and conference call announcements provide context on Sangamo’s operating expenses, cash position and strategic focus on a neurology‑oriented genomic medicine business. For readers interested in SGMO, this news page aggregates these clinical, regulatory, partnership and financial disclosures in one place, making it easier to follow the company’s reported milestones over time.
Sangamo Therapeutics has announced promising preliminary results from the Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. All four patients in the initial cohorts showed above-normal α-Gal A activity, maintained for up to one year. The company is planning a Phase 3 trial following these results, with one patient withdrawing from enzyme replacement therapy due to stable enzyme activity. There were no Grade 2 or higher adverse events reported.
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) has announced the release date for its third quarter 2021 financial results, set for November 4, 2021. Following the release, a conference call is scheduled at 9:15 a.m. ET, open to the public through telephone and webcast. Key details include dial-in numbers and a conference ID for participants. Sangamo is a clinical-stage biopharmaceutical firm focused on genomic medicines, leveraging proprietary technology to develop solutions for patients with unmet medical needs. For more information, visit sangamo.com.
Sangamo Therapeutics (NASDAQ: SGMO) has announced its participation in upcoming investor conferences. The 2021 Virtual Wells Fargo Healthcare Conference is scheduled for September 10 at 3:20 p.m. ET. Next, at the H.C. Wainwright & Co. 23rd Annual Global Investment Conference, Sangamo will present on September 13 at 7:00 a.m. ET. Lastly, the Morgan Stanley 19th Annual Global Healthcare Conference will take place on September 15 at 10:15 a.m. ET. Presentations will be available for webcasting and later on Sangamo's website under Events and Presentations.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) will participate in a fireside chat at the 2021 Wedbush PacGrow Healthcare Conference on August 11 at 2:55 PM Eastern Time. The virtual session will be webcast live, providing investors access to insights about the company's genomic medicines pipeline, which leverages zinc finger genome engineering technology. The presentation will be available for later viewing on Sangamo's website, ensuring that stakeholders can stay informed about its progress and strategies in the clinical-stage biopharmaceutical sector.
Sangamo Therapeutics (SGMO) announced its Q2 2021 financial results, reporting a net loss of $47.2 million or $0.33 per share, up from a loss of $35.9 million in 2020. Q2 revenues reached $27.9 million, a $6.3 million increase year-over-year, attributed to collaboration agreements with Novartis and Biogen. Operating expenses rose to $76.6 million from $59.4 million in Q2 2020. As of June 30, 2021, cash and equivalents totaled $578.9 million. The company reiterated its 2021 expense guidance of $285 million to $305 million.
Sangamo Therapeutics (Nasdaq: SGMO) announced the release of its second quarter 2021 financial results, scheduled for August 5, 2021, after market close. This will be followed by a conference call at 4:30 p.m. ET, open to the public via phone and webcast. During the call, the company will discuss its financial performance and provide updates on its business operations. Dial-in numbers are provided for domestic and international callers, and a replay will be available for one week post-call.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) has appointed Prathyusha Duraibabu as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Duraibabu, who previously served as Principal Accounting Officer, brings over 20 years of experience in financial strategy and operations. Her notable contributions include orchestrating a $140 million follow-on offering and aiding collaborations with Biogen and Novartis, raising an additional $425 million. CEO Sandy Macrae highlighted her leadership and experience in enhancing organizational efficiency.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced management will participate in a fireside chat at the Jefferies Healthcare Conference on June 4th at 11am ET. The session will be available via live webcast on the Sangamo Therapeutics website and will also be accessible after the event. Sangamo is dedicated to advancing genomic medicines, including gene therapy and genome engineering, with aims to transform patient care. For additional details, visit Sangamo's official website.
Sangamo Therapeutics (SGMO) reported Q1 2021 results, highlighting a net loss of $45.9 million or $0.32 per share, slightly more than the $42.9 million loss in Q1 2020. Total revenues surged to $26.3 million from $13.1 million due to license fees and research reimbursements. Key achievements included completing enrollment for the hemophilia A Phase 3 trial and receiving Fast Track Designation from the FDA for SAR445136, a therapy for sickle cell disease. Total operating expenses increased to $72.6 million, influenced by higher clinical and manufacturing costs. Cash reserves decreased to $629.5 million.
Sangamo Therapeutics (Nasdaq: SGMO) announced its participation in two investor conferences in May 2021. The first is the BofA Securities 2021 Health Care Conference, scheduled for May 13 at 1:15 p.m. Eastern Time. The second is the 2021 RBC Capital Markets Global Healthcare Conference on May 18 at 9:45 a.m. Eastern Time. Webcast links for these presentations will be available on the company's website under the Investors and Media section. Post-event recordings will also be accessible on the site.